Admission Rates Between 4.5 and 9 Months of Age and Admission Hazard Rate Ratio (HRR) for Early Recipients of Measles Vaccine (Group A), Compared With Controls (Groups B and C), by Neonatal Vitamin A Supplementation (NVAS) and Sex
| NVAS Status, Sex . | Group A . | Groups B and C . | Admission HRRa (95% CI) . | |||
|---|---|---|---|---|---|---|
| Admissions/100 Person- Years (Admissions/Person-Days), Children, No. . | Enrolled Children, No. . | Admissions/100 Person-Years (Admissions/Person-Days), Children, No. . | Enrolled Children, No. . | All Admissionsb . | Excluding Measles Admissions . | |
| Overall | ||||||
| Boys | 9.5 (37/142 037) | 1084 | 11.1 (86/282 311) | 2151 | 0.86 (0.58–1.26) | 0.96 (0.64–1.41) |
| Girls | 5.3 (20/137 120) | 1045 | 10.2 (78/278 905) | 2137 | 0.53 (0.32–0.86) | 0.59 (0.36–0.97) |
| All | 7.5 (57/279 157) | 2129 | 10.7 (164/561 216) | 4288 | 0.70 (0.52–0.95) | 0.78 (0.58–1.07) |
| No NVAS | ||||||
| Boys | 8.4 (17/73 485) | 558 | 11.4 (46/147 115) | 1130 | 0.73 (0.42–1.28) | 0.80 (0.46–1.41) |
| Girls | 3.0 (6/71 919) | 549 | 10.3 (43/152 213) | 1165 | 0.30 (0.13–0.70) | 0.35 (0.15–0.82) |
| All | 5.8 (23/145 404) | 1107 | 10.9 (89/299 328) | 2295 | 0.53 (0.34–0.84) | 0.60 (0.38–0.95) |
| NVAS | ||||||
| Boys | 10.6 (20/68 552) | 526 | 10.8 (40/135 196) | 1021 | 1.00 (0.58–1.71) | 1.14 (0.66–1.98) |
| Girls | 7.8 (14/65 201) | 496 | 10.1 (35/126 692) | 972 | 0.79 (0.42–1.46) | 0.83 (0.45–1.56) |
| All | 9.3 (34/133 753) | 1022 | 10.5 (75/261 888) | 1993 | 0.90 (0.60–1.35) | 0.99 (0.66–1.50) |
| NVAS Status, Sex . | Group A . | Groups B and C . | Admission HRRa (95% CI) . | |||
|---|---|---|---|---|---|---|
| Admissions/100 Person- Years (Admissions/Person-Days), Children, No. . | Enrolled Children, No. . | Admissions/100 Person-Years (Admissions/Person-Days), Children, No. . | Enrolled Children, No. . | All Admissionsb . | Excluding Measles Admissions . | |
| Overall | ||||||
| Boys | 9.5 (37/142 037) | 1084 | 11.1 (86/282 311) | 2151 | 0.86 (0.58–1.26) | 0.96 (0.64–1.41) |
| Girls | 5.3 (20/137 120) | 1045 | 10.2 (78/278 905) | 2137 | 0.53 (0.32–0.86) | 0.59 (0.36–0.97) |
| All | 7.5 (57/279 157) | 2129 | 10.7 (164/561 216) | 4288 | 0.70 (0.52–0.95) | 0.78 (0.58–1.07) |
| No NVAS | ||||||
| Boys | 8.4 (17/73 485) | 558 | 11.4 (46/147 115) | 1130 | 0.73 (0.42–1.28) | 0.80 (0.46–1.41) |
| Girls | 3.0 (6/71 919) | 549 | 10.3 (43/152 213) | 1165 | 0.30 (0.13–0.70) | 0.35 (0.15–0.82) |
| All | 5.8 (23/145 404) | 1107 | 10.9 (89/299 328) | 2295 | 0.53 (0.34–0.84) | 0.60 (0.38–0.95) |
| NVAS | ||||||
| Boys | 10.6 (20/68 552) | 526 | 10.8 (40/135 196) | 1021 | 1.00 (0.58–1.71) | 1.14 (0.66–1.98) |
| Girls | 7.8 (14/65 201) | 496 | 10.1 (35/126 692) | 972 | 0.79 (0.42–1.46) | 0.83 (0.45–1.56) |
| All | 9.3 (34/133 753) | 1022 | 10.5 (75/261 888) | 1993 | 0.90 (0.60–1.35) | 0.99 (0.66–1.50) |
Data are from the national pediatric ward, Guinea-Bissau. Early recipients received measles vaccine at 4.5 and 9 months of age, and controls received vaccine at 9 months of age.
Abbreviation: CI, confidence interval.
a Calculated as A/[A + B].
b With follow-up to only 9 months of age, the admission HRR was 0.72 (95% CI, 0.53–0.97) for all children, 0.53 (95% CI, 0.32–0.88) for girls, and 0.87 (95% CI, 0.59–1.29) for boys; among children who did not receive NVAS, the HRR was 0.56 (95% CI, 0.35–0.88) for all children, 0.32 (95% CI, 0.13–0.74) for girls, and 0.76 (95% CI, 0.43–1.33) for boys; for children who received NVAS, the HRR was 0.89 (95% CI, 0.59–1.35) for all children, 0.77 (95% CI, 0.40–1.46) for girls, and 1.00 (95% CI, 0.58–1.72) for boys.
Admission Rates Between 4.5 and 9 Months of Age and Admission Hazard Rate Ratio (HRR) for Early Recipients of Measles Vaccine (Group A), Compared With Controls (Groups B and C), by Neonatal Vitamin A Supplementation (NVAS) and Sex
| NVAS Status, Sex . | Group A . | Groups B and C . | Admission HRRa (95% CI) . | |||
|---|---|---|---|---|---|---|
| Admissions/100 Person- Years (Admissions/Person-Days), Children, No. . | Enrolled Children, No. . | Admissions/100 Person-Years (Admissions/Person-Days), Children, No. . | Enrolled Children, No. . | All Admissionsb . | Excluding Measles Admissions . | |
| Overall | ||||||
| Boys | 9.5 (37/142 037) | 1084 | 11.1 (86/282 311) | 2151 | 0.86 (0.58–1.26) | 0.96 (0.64–1.41) |
| Girls | 5.3 (20/137 120) | 1045 | 10.2 (78/278 905) | 2137 | 0.53 (0.32–0.86) | 0.59 (0.36–0.97) |
| All | 7.5 (57/279 157) | 2129 | 10.7 (164/561 216) | 4288 | 0.70 (0.52–0.95) | 0.78 (0.58–1.07) |
| No NVAS | ||||||
| Boys | 8.4 (17/73 485) | 558 | 11.4 (46/147 115) | 1130 | 0.73 (0.42–1.28) | 0.80 (0.46–1.41) |
| Girls | 3.0 (6/71 919) | 549 | 10.3 (43/152 213) | 1165 | 0.30 (0.13–0.70) | 0.35 (0.15–0.82) |
| All | 5.8 (23/145 404) | 1107 | 10.9 (89/299 328) | 2295 | 0.53 (0.34–0.84) | 0.60 (0.38–0.95) |
| NVAS | ||||||
| Boys | 10.6 (20/68 552) | 526 | 10.8 (40/135 196) | 1021 | 1.00 (0.58–1.71) | 1.14 (0.66–1.98) |
| Girls | 7.8 (14/65 201) | 496 | 10.1 (35/126 692) | 972 | 0.79 (0.42–1.46) | 0.83 (0.45–1.56) |
| All | 9.3 (34/133 753) | 1022 | 10.5 (75/261 888) | 1993 | 0.90 (0.60–1.35) | 0.99 (0.66–1.50) |
| NVAS Status, Sex . | Group A . | Groups B and C . | Admission HRRa (95% CI) . | |||
|---|---|---|---|---|---|---|
| Admissions/100 Person- Years (Admissions/Person-Days), Children, No. . | Enrolled Children, No. . | Admissions/100 Person-Years (Admissions/Person-Days), Children, No. . | Enrolled Children, No. . | All Admissionsb . | Excluding Measles Admissions . | |
| Overall | ||||||
| Boys | 9.5 (37/142 037) | 1084 | 11.1 (86/282 311) | 2151 | 0.86 (0.58–1.26) | 0.96 (0.64–1.41) |
| Girls | 5.3 (20/137 120) | 1045 | 10.2 (78/278 905) | 2137 | 0.53 (0.32–0.86) | 0.59 (0.36–0.97) |
| All | 7.5 (57/279 157) | 2129 | 10.7 (164/561 216) | 4288 | 0.70 (0.52–0.95) | 0.78 (0.58–1.07) |
| No NVAS | ||||||
| Boys | 8.4 (17/73 485) | 558 | 11.4 (46/147 115) | 1130 | 0.73 (0.42–1.28) | 0.80 (0.46–1.41) |
| Girls | 3.0 (6/71 919) | 549 | 10.3 (43/152 213) | 1165 | 0.30 (0.13–0.70) | 0.35 (0.15–0.82) |
| All | 5.8 (23/145 404) | 1107 | 10.9 (89/299 328) | 2295 | 0.53 (0.34–0.84) | 0.60 (0.38–0.95) |
| NVAS | ||||||
| Boys | 10.6 (20/68 552) | 526 | 10.8 (40/135 196) | 1021 | 1.00 (0.58–1.71) | 1.14 (0.66–1.98) |
| Girls | 7.8 (14/65 201) | 496 | 10.1 (35/126 692) | 972 | 0.79 (0.42–1.46) | 0.83 (0.45–1.56) |
| All | 9.3 (34/133 753) | 1022 | 10.5 (75/261 888) | 1993 | 0.90 (0.60–1.35) | 0.99 (0.66–1.50) |
Data are from the national pediatric ward, Guinea-Bissau. Early recipients received measles vaccine at 4.5 and 9 months of age, and controls received vaccine at 9 months of age.
Abbreviation: CI, confidence interval.
a Calculated as A/[A + B].
b With follow-up to only 9 months of age, the admission HRR was 0.72 (95% CI, 0.53–0.97) for all children, 0.53 (95% CI, 0.32–0.88) for girls, and 0.87 (95% CI, 0.59–1.29) for boys; among children who did not receive NVAS, the HRR was 0.56 (95% CI, 0.35–0.88) for all children, 0.32 (95% CI, 0.13–0.74) for girls, and 0.76 (95% CI, 0.43–1.33) for boys; for children who received NVAS, the HRR was 0.89 (95% CI, 0.59–1.35) for all children, 0.77 (95% CI, 0.40–1.46) for girls, and 1.00 (95% CI, 0.58–1.72) for boys.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
